A Systematic Review Of Fuzheng Huayu Capsule For Liver Fibrosis Of Chronic Hepatitis B

ObjectiveThe compound prescription traditional Chinese medicine treatment of liver fibrosis in liver disease research are our country's international characteristics.Its variety is numerous,but the research depth is irregular,and is currently less evidence-based medicine related reports,the evidence rank is not high.therefore,this article chooses its representation to Fuzheng Huayu capsule.To evaluate the effectiveness and safety of treatment with Fuzheng Huayu capsule for liver fibrosis of chronic hepatitis B(CHB).The aim for it is to provide reference for its clinical applications and further studies.MethodsWe searched MEDLINE,EMBASE,Cochrane Controlled Trials Register (CCTR),CBM and CNKI up to March 2008.The references of retrieved literature were also hand searched.Randomized controlled trials(RCT) which compared Fuzheng Huayu capsule with placebo or other drugs were collected. Data extraction and quality assessment were performed by two reviewers independently.The Cochrane Collaboration's software RevMan 4.2.10 was used for data analyses.Results Seven RCTs involving 590 cases of liver fibrosis of CHB were included. As for their methodological quality,according to the four evaluation criteria documents about RCT Articles of Cochrane Reviewer' Handbook 4.2.2.One was graded A,one was graded B and the others were graded C.We carried out subgroup analyses based on treatment course and intervention measures.In terms of reducing hyaluronic acid,Fuzheng Huayu capsule was more effective than Huoluo Shugan capsule when the treatment course was 3 months (WMD=-61.75,95%CI-105.20 to-18.30);significant differences were also noted between Fuzheng Huayu capsule and placebo(WMD=-187.72, 95%CI-244.23 to-31.21) or Huoluo Shugan capsule(WMD=-120.03, 95%CI-158.41 to-81.65) when the treatment course was 6 months.In terms of reducing IV-C,Fuzheng Huayu capsule was more effective than Gantaile when the treatment course was 6 months(WMD=-72.32,95%CI-84.30 to-60.34).As for improving liver fibrosis at stage S,significant differences were observed between Fuzheng Huayu capsule and Gantaile (RR=2.33,95%CI 1.37 to 3.96) or Huoluo Shugan capsule(RR=1.30,95%CI 1.03 to 1.65).Except a very small number of gastrointestinal reactions,no Significant adverse reactions were reported.ConclusionFuzheng Huayu capsule is effective in reducing hyaluronic acid and the stage of liver fibrosis,especially when the treatment course is prolonged from 3 months to 6 months.No significant adverse reactions are reported.